Intensive Care Unit, Centre Hospitalier de Versailles - Site André Mignot, 177 rue de Versailles, 78150 Le Chesnay Cedex, France.
Intensive Care Unit, Centre Hospitalier d'Angoulême, Rond point de Girac, 16959 Angoulême, France.
Seizure. 2018 Oct;61:170-176. doi: 10.1016/j.seizure.2018.08.022. Epub 2018 Aug 28.
Few outcome data are available about morbidity associated with endotracheal intubation modalities in critically ill patients with convulsive status epilepticus. We compared etomidate versus sodium thiopental for emergency rapid sequence intubation in patients with out-of-hospital convulsive status epilepticus.
Patients admitted to our intensive care unit in 2006-2015 were studied retrospectively. The main outcome measure was seizure and/or status epilepticus recurrence within 12 h after rapid sequence intubation.
We included 97 patients (60% male; median age, 59 years [IQR, 48-70]). Median time from seizure onset to first antiepileptic drug was 60 min [IQR, 35-90]. Reasons for intubation were coma in 95 (98%), acute respiratory distress in 18 (19%), refractory convulsive status epilepticus in 9 (9%), and shock in 6 (6%) patients; 50 (52%) patients had more than one reason. The hypnotic drugs used were etomidate in 54 (56%) and sodium thiopental in 43 (44%) patients. Seizure and/or status epilepticus recurred in 13 (56%) patients in the etomidate group and 11 patients (44%) in the sodium thiopental group (adjusted common odds ratio [aOR], 0.98; 95%CI, 0.36-2.63; P = 0.97). The two groups were not significantly different for proportions of patients with hemodynamic instability after intubation (aOR, 0.60; 95%CI, 0.23-1.58; P = 0.30) or with difficult endotracheal intubation (OR, 1.28; 95% CI 0.23 to 7.21; P=0.77).
Our findings argue against a difference in seizure and/or status epilepticus recurrences rates between critically ill patients with convulsive status epilepticus given etomidate vs. sodium thiopental as the induction agent for emergency intubation.
关于伴有惊厥性癫痫持续状态的危重症患者中,不同气管内插管方式与发病率相关的结果数据很少。我们比较了依托咪酯与硫喷妥钠在院外惊厥性癫痫持续状态患者中进行紧急快速序贯插管的情况。
回顾性研究了 2006 年至 2015 年入住我院重症监护病房的患者。主要观察指标为快速序贯插管后 12 小时内癫痫发作和/或癫痫持续状态复发。
共纳入 97 例患者(60%为男性;中位年龄 59 岁[IQR,48-70])。从癫痫发作到首次使用抗癫痫药物的中位时间为 60 分钟[IQR,35-90]。插管的原因是昏迷 95 例(98%)、急性呼吸窘迫 18 例(19%)、难治性惊厥性癫痫持续状态 9 例(9%)和休克 6 例(6%);50 例(52%)患者有不止一个原因。所用的镇静药物为依托咪酯 54 例(56%)和硫喷妥钠 43 例(44%)。依托咪酯组有 13 例(56%)和硫喷妥钠组有 11 例(44%)患者出现癫痫发作和/或癫痫持续状态复发(调整后共同优势比[aOR],0.98;95%CI,0.36-2.63;P=0.97)。两组患者在插管后发生血流动力学不稳定的比例(aOR,0.60;95%CI,0.23-1.58;P=0.30)或气管插管困难的比例(OR,1.28;95%CI,0.23-7.21;P=0.77)差异无统计学意义。
我们的研究结果表明,在因惊厥性癫痫持续状态而行紧急插管的危重症患者中,给予依托咪酯与硫喷妥钠作为诱导药物,其癫痫发作和/或癫痫持续状态复发率无差异。